Analysis of the results of prostate cancer biopsies performed after a 10-year interval
https://doi.org/10.17650/1726-9776-2008-4-3-53-57
Abstract
Introduction and objective: the authors compared the results of biopsies performed in 1994 and 2004, respectively.
The analysis of the results of prostate biopsy obtained in 1994 and 2004 was carried out. Prostate cancer is the most common malignant tumor in males; its diagnostic algorithm and therapy were analyzed. The aim of the study was to compare data from the prostate biopsies performed in 1994 with those of 2004. During this decade, 4.5 fold increase of the number of prostate biopsies has been observed. In 1994, 36.2%, while in 2004, 47.5% of the biopsies proved to be a cancer. The mean age of the patients undergoing biopsy decreased from 69.7 to 62.3 years; however, the mean age of patients who were suffering from prostate cancer remained constant (70.8 vs. 71.3 years).
Conclusions: Whereas in 1994 only the total level of PSA was estimated, in 2004 the diagnostic algorithm included additional measurements of free-PSA and PSA-density. Prostate biopsy was performed by a trans-rectal ultrasound guided technique unlike the blind or trans-perineal methods which were only available previously. Although the effectiveness of the prostate biopsy is improved, the diagnosis and identification of prostate cancer at a younger age remains to be a challenge. The Gleason score marking the aggressiveness of the prostate cancers was lower; therefore, more patients were found suitable for curative surgery. However, the increased mean value of PSA level indicated that patients were still rather of a more advanced stage in majority, which could only be treated by palliative therapy.
About the Authors
I. RomicsHungary
Department of Urology
G. Banfi
Hungary
Department of Urology
T. Glasz
Hungary
2nd Department of Pathology
E. Szekely
Hungary
2nd Department of Pathology
References
1. Romics I., Fischer G., Bе ’ ly M. et al. Experience with prostate cancer screening. Magy Urol (Hung Urol in Hungarian) 1998;10:428—32.
2. Oliver S.E., Gunnel D., Donovan J.L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000;355:1788—9.
3. Brawer M.K., Chetner M.P., Beatle J. et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841—5.
4. Benson M.C., Whang I.S., Olsson C.A. et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817—21.
5. Romics I. Prognostic factors of prostate cancer. Magy Urol (Hung Urol in Hungarian) 1998;10:103—9.
6. Romics I. The technique of ultrasound guided prostate biopsy. World J Urol 2004;22:353—6.
7. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273—9.
8. Neal D.E., Clejan S., Sarma D. et al. Prostate specific antigen and prostatitis. Prostate 1992;20:105—11.
9. Pajor L., Kisbenedek L., Romics I. Therapy of prostate cancer. Magy Urol (Hung Urol in Hungarian) 2003;15:46—55.
10. Stamey T.A., Caldwell M., McNeal J.E. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297—301.
11. De Koning H.J., Auvinen A., Berenguer Sanchez A. et al. Large-scale randomized prostatae cancer screening trials: program performances in the european randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002;97:237—44.
Review
For citations:
Romics I., Banfi G., Glasz T., Szekely E. Analysis of the results of prostate cancer biopsies performed after a 10-year interval. Cancer Urology. 2008;4(3):53-57. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-3-53-57